#3 - GW Pharmaceuticals (NASDAQ:GWPH)
GW Pharmaceuticals (NASDAQ: GWPH) - If there’s one thing that 2018 has taught us is that cannabis – and all the related controversy around it – is not going away. However, controversy frequently brings opportunity and that is the case for GW Pharmaceuticals. Investing in biotech is already risky. GWPH takes that risk to a new level because it develops its drugs from marijuana. But whereas some companies in this space are in the penny stock category, GWPH actually has two products that show legitimate market potential. A leading candidate that is still in development is Epidiolex, which is designed to treat Dravet Syndrome and Lennox-Gastaut Syndrome. The other, Savilex, which is designed to treat the spasticity brought on by multiple sclerosis, is already on the market. GWPH is developing a compound based on Savilex that offers a potential treatment for epilepsy as well as autism spectrum disorders. In this competitive space, a promising pipeline has significant appeal to investors. If Epidiolex can get regulatory approval, the most likely path for the company will be as an acquisition target. And if that happens, the company’s stock may surge even beyond its impressive growth of nearly 70% since the beginning of the year.
About GW Pharmaceuticals
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
Read More - Current Price
- $218.96
- Consensus Rating
- N/A
- Ratings Breakdown
- 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- N/A
